DiaMedica Therapeutics (id:5825 DMAC)
4.70 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/23/2024 1:22:25 PM)
Exchange closed, opens in 1 day 20 hours
About DiaMedica Therapeutics
Market Capitalization 171.47M
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
| Headquarters (address) |
301 Carlson Parkway Minneapolis 55305 MN United States |
| Phone | (763) 496-5454 |
| Website | https://www.diamedica.com |
| Employees | 18 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | DMAC |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 2.14 - 4.95 |
| Market Capitalization | 171.47M |
| P/E trailing | -7.83 |
| P/E forward | -5.42 |
| Price/Book | 2.98 |
| Beta | 1.46 |
| EPS | -0.510 |
| EPS United States (ID:6, base:3400) | 24.26 |